The report “Global Diabetic neuropathy Market” for the projected period 2016 to 2021 has been segmented on three different parameters. The global diabetic neuropathy market has been primarily studied on the basis of different categories of Diabetic neuropathy such as Peripheral, Autonomic neuropathy and so on. The Diabetic neuropathy market has also been studied on the basis of different treatment methods such as Antidepressants for e.g. Duloxetine (Cymbalta), Nortriptyline, Electrical Nerve Stimulation and many more. The market has also been studied on the premise of different geographies and the penetration of Diabetic neuropathy disease in those geographies.
North America is currently the dominating the global diabetic neuropathy market, followed by Europe. This can be attributed to the increasing number of patients with diabetes, surge in research and development activities on cure of diabetes or its related complications, and developing healthcare infrastructure in the region. The diabetic neuropathy market in Asia is expected to attain significant growth rate in the coming years. In addition, increasing number of diabetic patients in developing countries such as India, China, and Japan are expected to lead growth in the Asian diabetic neuropathy market. Increasing prevalence of diabetes cases, aging population are some of the key factors driving the global diabetic neuropathy market. However, the global diabetic neuropathy market is being restrained by factors such as the high failure rate of the clinical trials, stringent government regulations.
Following are the few leading companies present in the global Diabetic neuropathy market:
Mitsubishi Tanabe Pharma Corporation.
The Diabetic neuropathy market report also comprises of the leading companies profiled in an extremely descriptive manner. The company profiles include financial summaries, strategies, recent developments and product portfolios of the leading companies in the Diabetic neuropathy market. The report also incorporates a profound study of the market entropy, market forces and strategic analysis of the Diabetic neuropathy market.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Diabetic neuropathy – Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Diabetic neuropathy – Market Forces
4.1. Market Drivers
4.2. Market Constraints
4.3. Market Challenges
4.4. Attractiveness of the Diabetic neuropathy Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition
5. Diabetic neuropathy Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Diabetic neuropathy Market – By Type
6.1. Peripheral Neuropathy
6.2. Autonomic Neuropathy
6.3. Proximal Neuropathy
6.4. Focal Neuropathy
7. Diabetic neuropathy Market – By Treatment Methods
7.1.1. Duloxetine (Cymbalta)
7.1.2. Nortriptyline (Pamelor, Aventyl)
7.1.3. Desipramine (Norpramin)
7.2. Anti-seizure medications
7.4. Electrical Nerve Stimulation
7.5. Topical Medications
8. Diabetic neuropathy Market- By Geography
8.2. Global Study
8.6.1. Middle East
9. Market Entropy
9.1. New Product Launches
9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles
10.1. NeuroMetrix, Inc.
10.2. Allergan PLC
10.3. Mitsubishi Tanabe Pharma Corporation.
10.4. Pfizer, Inc.
10.5. Novartis AG
10.6. AbbVie, Inc.
10.7. Eli Lilly
10.8. Merck & Co., Inc.
10.10. GlaxoSmithKline plc
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.5. Compilation of Expert Insights